JP2008543860A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008543860A5 JP2008543860A5 JP2008517067A JP2008517067A JP2008543860A5 JP 2008543860 A5 JP2008543860 A5 JP 2008543860A5 JP 2008517067 A JP2008517067 A JP 2008517067A JP 2008517067 A JP2008517067 A JP 2008517067A JP 2008543860 A5 JP2008543860 A5 JP 2008543860A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- propyl
- ethyl
- phenyl
- trifluoromethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 6
- KXKVLQRXCPHEJC-UHFFFAOYSA-N Methyl acetate Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 206010001897 Alzheimer's disease Diseases 0.000 claims 2
- 208000006673 Asthma Diseases 0.000 claims 2
- UUIQMZJEGPQKFD-UHFFFAOYSA-N Methyl butyrate Chemical compound CCCC(=O)OC UUIQMZJEGPQKFD-UHFFFAOYSA-N 0.000 claims 2
- 208000009025 Nervous System Disease Diseases 0.000 claims 2
- 206010029305 Neurological disorder Diseases 0.000 claims 2
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 2
- 230000002757 inflammatory Effects 0.000 claims 2
- CNMFHDIDIMZHKY-UHFFFAOYSA-N methyl 2,2-dimethylpropanoate Chemical compound COC(=O)C(C)(C)C CNMFHDIDIMZHKY-UHFFFAOYSA-N 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- -1 3- (trifluoromethyl) phenyl Chemical group 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000008665 Gastrointestinal Disease Diseases 0.000 claims 1
- 210000001035 Gastrointestinal Tract Anatomy 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010061536 Parkinson's disease Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 229940121359 adenosine receptor antagonists Drugs 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 201000001320 atherosclerosis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000008286 diarrhea Diseases 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 claims 1
- 201000002146 gastrointestinal system disease Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- CAAULPUQFIIOTL-UHFFFAOYSA-N methyl dihydrogen phosphate Chemical compound COP(O)(O)=O CAAULPUQFIIOTL-UHFFFAOYSA-N 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 0 *C[n]1ncc(-c2nc(N(*)C(N(*)C3=O)=O)c3[n]2C(*)*)c1 Chemical compound *C[n]1ncc(-c2nc(N(*)C(N(*)C3=O)=O)c3[n]2C(*)*)c1 0.000 description 1
Claims (21)
- R1およびR2が、独立してエチルまたはn−プロピルである、請求項1に記載の化合物。
- R4が、3−(トリフルオロメチル)フェニルである、請求項1に記載の化合物。
- R1がn−プロピルであり、そしてR2がエチルである、請求項3に記載の化合物。
- Xが水素である、請求項4に記載の化合物。
- Yが、−C(O)Rである、請求項5に記載の化合物。
- Rが、メチル、エチル、n−プロピル、イソプロピル、n−ブチル、イソブチル、t−ブチル、またはn−ペンチルである、請求項6に記載の化合物。
- Rがメチルである請求項7に記載の化合物、すなわち、[3−エチル−2,6−ジオキソ−1−プロピル−8−(1−{[3−(トリフルオロメチル)フェニル]メチル}ピラゾール−4−イル]−1,3,7−トリヒドロプリン−7−イル]メチルアセテート。
- Rがn−プロピルである請求項7に記載の化合物、すなわち、[3−エチル−2,6−ジオキソ−1−プロピル−8−(1−{[3−(トリフルオロメチル)フェニル]メチル}ピラゾール−4−イル]−1,3,7−トリヒドロプリン−7−イル]メチルブタノエート。
- Rがt−ブチルである請求項7に記載の化合物、すなわち、[3−エチル−2,6−ジオキソ−1−プロピル−8−(1−{[3−(トリフルオロメチル)フェニル]メチル}ピラゾール−4−イル]−1,3,7−トリヒドロプリン−7−イル]メチル2,2−ジメチルプロパノエート。
- Yが−P(O)(OR5)2である、請求項5に記載の化合物。
- R5が水素である請求項11に記載の化合物、すなわち、リン酸二水素[3−エチル−2,6−ジオキソ−1−プロピル−8−(1−{[3−(トリフルオロメチル)フェニル]メチル}−ピラゾール−4−イル)(1,3,7−トリヒドロプリン−7−イル)メチル。
- A2Bアデノシンレセプターアンタゴニストでの処置により軽減可能である哺乳動物における疾患状態を処置するための組成物であって、請求項1に記載の化合物の治療的に有効な用量を含む、組成物。
- 前記請求項1に記載の化合物が、[3−エチル−2,6−ジオキソ−1−プロピル−8−(1−{[3−(トリフルオロメチル)フェニル]メチル}ピラゾール−4−イル]−1,3,7−トリヒドロプリン−7−イル]メチルアセテート、[3−エチル−2,6−ジオキソ−1−プロピル−8−(1−{[3−(トリフルオロメチル)フェニル]メチル}ピラゾール−4−イル]−1,3,7−トリヒドロプリン−7−イル]メチルブタノエート、[3−エチル−2,6−ジオキソ−1−プロピル−8−(1−{[3−(トリフルオロメチル)フェニル]メチル}ピラゾール−4−イル]−1,3,7−トリヒドロプリン−7−イル]メチル2,2−ジメチルプロパノエート、およびリン酸二水素[3−エチル−2,6−ジオキソ−1−プロピル−8−(1−{[3−(トリフルオロメチル)フェニル]メチル}−ピラゾール−4−イル)(1,3,7−トリヒドロプリン−7−イル)メチルからなる群から選択される、請求項13に記載の組成物。
- 前記疾患状態が、アテローム性動脈硬化症、新脈管形成、糖尿病性網膜症、癌、慢性閉塞性肺疾患、および喘息から選択される、請求項14に記載の組成物。
- 前記疾患状態が、喘息である、請求項15に記載の組成物。
- 前記疾患状態が、炎症性胃腸管障害である、請求項14に記載の組成物。
- 前記炎症性胃腸管障害が、下痢である、請求項17に記載の組成物。
- 前記疾患状態が、神経学的障害である、請求項14に記載の組成物。
- 前記神経学的障害が、老人痴呆、アルツハイマー病、またはパーキンソン病である、請求項19に記載の組成物。
- 少なくとも1つの薬学的に受容可能な賦形剤と、薬学的に有効な量の請求項1に記載の化合物とを含む、薬学的組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69140805P | 2005-06-16 | 2005-06-16 | |
US60/691,408 | 2005-06-16 | ||
PCT/US2006/023167 WO2006138376A1 (en) | 2005-06-16 | 2006-06-14 | Prodrugs of a2b adenosine receptor antagonists |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2008543860A JP2008543860A (ja) | 2008-12-04 |
JP2008543860A5 true JP2008543860A5 (ja) | 2009-06-25 |
JP5044823B2 JP5044823B2 (ja) | 2012-10-10 |
Family
ID=37215988
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008517067A Expired - Fee Related JP5044823B2 (ja) | 2005-06-16 | 2006-06-14 | A2bアデノシンレセプターアンタゴニストのプロドラッグ |
Country Status (14)
Country | Link |
---|---|
US (3) | US7625881B2 (ja) |
EP (2) | EP2301937A1 (ja) |
JP (1) | JP5044823B2 (ja) |
KR (1) | KR20080016645A (ja) |
CN (1) | CN101198608B (ja) |
AU (1) | AU2006259411B2 (ja) |
CA (1) | CA2612344A1 (ja) |
IL (1) | IL188103A0 (ja) |
MX (1) | MX2007015909A (ja) |
NO (1) | NO20080278L (ja) |
NZ (1) | NZ564326A (ja) |
RU (2) | RU2415858C2 (ja) |
WO (1) | WO2006138376A1 (ja) |
ZA (1) | ZA200710878B (ja) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080194593A1 (en) * | 2001-11-09 | 2008-08-14 | Rao Kalla | A2b adenosine receptor antagonists |
US7317017B2 (en) | 2002-11-08 | 2008-01-08 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
US20080318983A1 (en) * | 2001-11-09 | 2008-12-25 | Rao Kalla | A2b adenosine receptor antagonists |
AU2004268964B2 (en) * | 2003-08-25 | 2010-03-11 | Allergan Sales, Llc | Substituted 8-heteroaryl xanthines |
NZ589657A (en) | 2004-10-15 | 2012-06-29 | Gilead Palo Alto Inc | Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists |
US7579348B2 (en) * | 2005-02-25 | 2009-08-25 | Pgxhealth, Llc | Derivatives of 8-substituted xanthines |
US7618962B2 (en) * | 2005-02-25 | 2009-11-17 | Pgx Health, Llc | Pyrazolyl substituted xanthines |
WO2006091936A2 (en) | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines |
EP2301937A1 (en) | 2005-06-16 | 2011-03-30 | Cv Therapeutics, Inc. | Prodrugs of A2b adenosine receptor antagonists |
US7795268B2 (en) * | 2006-03-17 | 2010-09-14 | Gilead Palo Alto, Inc. | Method of treating hepatic disease using A2B adenosine receptor antagonists |
US7884100B2 (en) * | 2006-06-16 | 2011-02-08 | Pgxhealth, Llc | Substituted 8-[6-amino-3-pyridyl]xanthines |
US7767685B2 (en) * | 2006-06-29 | 2010-08-03 | King Pharmaceuticals Research And Development, Inc. | Adenosine A2B receptor antagonists |
WO2009088518A1 (en) * | 2008-01-11 | 2009-07-16 | Cv Therapeutics, Inc. | A2b adenosine receptor antagonists for the treatment of cancer |
WO2009157938A1 (en) * | 2008-06-26 | 2009-12-30 | Cv Therapeutics, Inc. | A2b adenosine receptor antagonists for treating cancer |
AU2010339691B2 (en) | 2010-01-07 | 2015-04-02 | Alkermes Pharma Ireland Limited | Prodrugs of heteraromatic compounds |
CN103237548A (zh) * | 2010-06-30 | 2013-08-07 | 吉利德科学股份有限公司 | A2b腺苷受体拮抗剂用于治疗肺高血压的应用 |
EP2616470B1 (en) | 2010-09-13 | 2016-10-12 | Advinus Therapeutics Limited | Purine compounds as prodrugs of a2b adenosine receptor antagonists, their process and medicinal applications |
AR085942A1 (es) | 2011-04-07 | 2013-11-06 | Gilead Sciences Inc | Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio |
JP2014514300A (ja) * | 2011-04-08 | 2014-06-19 | スファエラ ファーマ ピーティーイー リミテッド | 置換メチルホルミル試薬並びに化合物の物理化学的性質及び/又は薬物動態学的性質を改質するためのそれらの使用方法 |
ES2656087T3 (es) | 2012-06-08 | 2018-02-23 | Gilead Sciences, Inc. | Inhibidores macrocíclicos de virus Flaviviridae |
AR091279A1 (es) | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
JP6209601B2 (ja) | 2012-06-08 | 2017-10-04 | ギリアード サイエンシーズ, インコーポレイテッド | フラビウイルス科ウイルスの大環状阻害剤 |
ES2580702B1 (es) | 2015-02-25 | 2017-06-08 | Palobiofarma, S.L. | Derivados de 2-aminopiridina como antagonistas del receptor A2b de adenosina y ligandos del receptor MT3 de melatonina |
US10308671B2 (en) * | 2015-12-14 | 2019-06-04 | Max-Planck-Gesellschaft Zur Forderung | Water-soluble derivatives of 3,5-diphenyl-diazole compounds |
CA3093234A1 (en) | 2018-03-05 | 2019-09-12 | Teon Therapeutics, Inc. | Adenosine receptor antagonists and uses thereof |
JP7156154B2 (ja) * | 2019-04-18 | 2022-10-19 | 株式会社島津製作所 | 培地処理システム及び培地処理方法 |
TW202327612A (zh) * | 2021-09-10 | 2023-07-16 | 美商天恩治療有限公司 | 使用腺苷受體拮抗劑之改良療法 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
US6117878A (en) * | 1998-02-24 | 2000-09-12 | University Of Virginia | 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors |
US6815446B1 (en) * | 1999-08-31 | 2004-11-09 | Vanderbilt University | Selective antagonists of A2B adenosine receptors |
EP1255550A2 (en) * | 2000-02-17 | 2002-11-13 | Cv Therapeutics, Inc. | Method for identifying and using a 2b adenosine receptor antagonists to mediate mammalian cell proliferation |
US6387913B1 (en) * | 2000-12-07 | 2002-05-14 | S. Jamal Mustafa | Method of treating airway diseases with combined administration of A2B and A3 adenosine receptor antagonists |
US20030235555A1 (en) * | 2002-04-05 | 2003-12-25 | David Shealey | Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses |
CN100467469C (zh) * | 2001-11-09 | 2009-03-11 | Cv医药有限公司 | A2b腺苷受体拮抗剂 |
US7125993B2 (en) * | 2001-11-09 | 2006-10-24 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
US7317017B2 (en) * | 2002-11-08 | 2008-01-08 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
US7304070B2 (en) * | 2001-11-09 | 2007-12-04 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
US20080318983A1 (en) * | 2001-11-09 | 2008-12-25 | Rao Kalla | A2b adenosine receptor antagonists |
US6977300B2 (en) | 2001-11-09 | 2005-12-20 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
WO2003053366A2 (en) * | 2001-12-20 | 2003-07-03 | Osi Pharmaceuticals, Inc. | Pyrimidine a2b selective antagonist compounds, their synthesis and use |
EP1601649A4 (en) * | 2003-02-19 | 2009-03-04 | Endacea Inc | A1-adenosine receptor antagonistic |
DK1622908T3 (da) * | 2003-05-06 | 2008-11-17 | Cv Therapeutics Inc | Xanthin-derivater som A2B adenosin-receptor-antagonister |
AU2004268964B2 (en) * | 2003-08-25 | 2010-03-11 | Allergan Sales, Llc | Substituted 8-heteroaryl xanthines |
MXPA06004789A (es) * | 2003-10-31 | 2006-07-03 | Cv Therapeutics Inc | Antagonistas del receptor de adenosina a2b. |
SI1789053T1 (sl) * | 2004-09-01 | 2012-09-28 | Gilead Sciences Inc | Postopek celjenja rane z uporabo antagonistov A2B adenozinskih receptorjev |
NZ589657A (en) * | 2004-10-15 | 2012-06-29 | Gilead Palo Alto Inc | Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists |
EP2301937A1 (en) * | 2005-06-16 | 2011-03-30 | Cv Therapeutics, Inc. | Prodrugs of A2b adenosine receptor antagonists |
US7795268B2 (en) * | 2006-03-17 | 2010-09-14 | Gilead Palo Alto, Inc. | Method of treating hepatic disease using A2B adenosine receptor antagonists |
ES2437871T3 (es) * | 2006-07-07 | 2014-01-14 | Gilead Sciences, Inc. | Moduladores del receptor tipo toll 7 |
CN102015712A (zh) * | 2008-03-26 | 2011-04-13 | 阿德维纳斯治疗私人有限公司 | 作为腺苷受体拮抗剂的杂环化合物 |
-
2006
- 2006-06-14 EP EP10011665A patent/EP2301937A1/en not_active Withdrawn
- 2006-06-14 JP JP2008517067A patent/JP5044823B2/ja not_active Expired - Fee Related
- 2006-06-14 AU AU2006259411A patent/AU2006259411B2/en not_active Ceased
- 2006-06-14 RU RU2007146669/04A patent/RU2415858C2/ru not_active IP Right Cessation
- 2006-06-14 CA CA002612344A patent/CA2612344A1/en not_active Abandoned
- 2006-06-14 CN CN2006800213389A patent/CN101198608B/zh not_active Expired - Fee Related
- 2006-06-14 MX MX2007015909A patent/MX2007015909A/es active IP Right Grant
- 2006-06-14 NZ NZ564326A patent/NZ564326A/en not_active IP Right Cessation
- 2006-06-14 WO PCT/US2006/023167 patent/WO2006138376A1/en active Application Filing
- 2006-06-14 KR KR1020077029351A patent/KR20080016645A/ko not_active Application Discontinuation
- 2006-06-14 EP EP06773161A patent/EP1891070A1/en not_active Withdrawn
- 2006-06-14 US US11/453,414 patent/US7625881B2/en active Active
-
2007
- 2007-12-13 IL IL188103A patent/IL188103A0/en unknown
- 2007-12-14 ZA ZA200710878A patent/ZA200710878B/xx unknown
-
2008
- 2008-01-15 NO NO20080278A patent/NO20080278L/no not_active Application Discontinuation
-
2009
- 2009-11-13 US US12/618,390 patent/US20100056538A1/en not_active Abandoned
-
2010
- 2010-12-09 RU RU2010150615/04A patent/RU2010150615A/ru not_active Application Discontinuation
-
2011
- 2011-01-21 US US13/011,446 patent/US8143249B2/en not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2008543860A5 (ja) | ||
RU2007146669A (ru) | Пролекарства антагонистов a2b рецептора аденозина | |
JP2009539828A5 (ja) | ||
JP2006510676A5 (ja) | ||
JP5575357B2 (ja) | 組織因子産生抑制剤 | |
JP2006504658A5 (ja) | ||
JP2008518890A5 (ja) | ||
JP2005508349A5 (ja) | ||
JP2008513358A5 (ja) | ||
JP2008518904A5 (ja) | ||
JP2007518738A5 (ja) | ||
JP2011526924A5 (ja) | ||
JP2015536320A5 (ja) | ||
JP2007509947A5 (ja) | ||
JP2013542937A5 (ja) | ||
JP2008500999A5 (ja) | ||
JP2014500861A5 (ja) | ||
JP2011500638A5 (ja) | ||
JP2009501745A5 (ja) | ||
JP2009543795A5 (ja) | ||
JP2012523440A5 (ja) | ||
US8772327B2 (en) | Phenylpropionic acid derivative and use thereof | |
JP2009543792A5 (ja) | ||
JP2013538857A5 (ja) | ||
JP2011509308A5 (ja) |